Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancerdoes tumor entity matter?
Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer
does tumor entity matter?
View/Date of Publication
26.06.2023Publisher
AME Publishing CompanyPublisher Location
Hong KongMetadata
Show full item record
Citable Link (Handle URI) 
https://hdl.handle.net/20.500.11811/13555
Abstract
Background: SARS-CoV-2 immunogenicity in patients with gastrointestinal cancer (GI cancer) following second and third vaccination was analyzed.
Methods: A total of 125 patients under active anticancer therapy or in follow-up care were included in this prospective study. Seroprevalence of SARS-CoV-2 anti-spike and surrogate neutralization antibodies (NABs) was measured.
Results: Four weeks after second vaccination, adequate titers of SARS-CoV-2 anti-spike immunoglobulin G (IgG) [≥282.0 binding antibody units (BAU)/mL] were found in 62.2% of patients under treatment versus 96.3% of patients in follow-up care (P<0.01). Sufficient titers of SARS-CoV-2 surrogate NAB (≥85.0%) were found in 32.7% of patients under treatment versus 70.6% in follow-up care (P<0.01). Titers of SARS-CoV-2 anti-spike IgG were especially low in patients with colorectal cancer (CRC). For SARS-CoV-2 surrogate NAB, patients with hepatocellular carcinoma (HCC) and with pancreaticobiliary cancer showed the lowest titers (P<0.01). SARSCoV-2 anti-spike IgG and SARS-CoV-2 surrogate NAB were associated with a correlation coefficient of 0.93. Reaching a titer of SARS-CoV-2 anti-spike IgG ≥482.0 BAU/mL, protective levels of SARS-CoV-2 surrogate NAB (≥85.0%) could be assumed. Following booster vaccination, all patients reached effective antibody titers.
Conclusions: Patients with active GI cancer showed impaired immunogenicity after second SARS-CoV-2 vaccination which was overcome by booster vaccination. Our findings were tumor-related and pronounced in patients with CRC and HCC. Waning immunity over time and antibody escape phenomena by variant of concern Omicron must be considered in these especially vulnerable patients.
Methods: A total of 125 patients under active anticancer therapy or in follow-up care were included in this prospective study. Seroprevalence of SARS-CoV-2 anti-spike and surrogate neutralization antibodies (NABs) was measured.
Results: Four weeks after second vaccination, adequate titers of SARS-CoV-2 anti-spike immunoglobulin G (IgG) [≥282.0 binding antibody units (BAU)/mL] were found in 62.2% of patients under treatment versus 96.3% of patients in follow-up care (P<0.01). Sufficient titers of SARS-CoV-2 surrogate NAB (≥85.0%) were found in 32.7% of patients under treatment versus 70.6% in follow-up care (P<0.01). Titers of SARS-CoV-2 anti-spike IgG were especially low in patients with colorectal cancer (CRC). For SARS-CoV-2 surrogate NAB, patients with hepatocellular carcinoma (HCC) and with pancreaticobiliary cancer showed the lowest titers (P<0.01). SARSCoV-2 anti-spike IgG and SARS-CoV-2 surrogate NAB were associated with a correlation coefficient of 0.93. Reaching a titer of SARS-CoV-2 anti-spike IgG ≥482.0 BAU/mL, protective levels of SARS-CoV-2 surrogate NAB (≥85.0%) could be assumed. Following booster vaccination, all patients reached effective antibody titers.
Conclusions: Patients with active GI cancer showed impaired immunogenicity after second SARS-CoV-2 vaccination which was overcome by booster vaccination. Our findings were tumor-related and pronounced in patients with CRC and HCC. Waning immunity over time and antibody escape phenomena by variant of concern Omicron must be considered in these especially vulnerable patients.
Subjects
Vaccination for SARS-CoV-2, gastrointestinal cancer, SARS-CoV-2 immunogenicity, SARS-CoV-2 surrogate neutralization antibodies, vaccination failure
Classification (DDC)
610 Medizin, GesundheitPublished in
Journal of gastrointestinal oncology, 2023, vol. 14, iss. 3, pp. 1218-1234First Publication
https://doi.org/10.21037/jgo-22-1065Monin, Malte Benedikt; Gorny, Jens Gabriel; Berger, Moritz; Baier, Leona I.; Zhou, Taotao; Mahn, Robert; Sadeghlar, Farsaneh; Möhring, Christian; Boesecke, Christoph; van Bremen, Kahtrin; Rieke, Gereon J.; Schlabe, Stefan; Breitschwerdt, Stefan; Marinova, Milka; Schmidt-Wolf, Ingo G. H.; Strassburg, Christian P.; Eis-Hübinger, Anna-Maria; Gonzalez-Carmona, Maria A.: Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer : does tumor entity matter?. In: Journal of gastrointestinal oncology. 2023, vol. 14, iss. 3, 1218-1234.
Online-Ausgabe in bonndoc: https://hdl.handle.net/20.500.11811/13555
Online-Ausgabe in bonndoc: https://hdl.handle.net/20.500.11811/13555
@article{handle:20.500.11811/13555,
author = {{Malte Benedikt Monin} and {Jens Gabriel Gorny} and {Moritz Berger} and {Leona I. Baier} and {Taotao Zhou} and {Robert Mahn} and {Farsaneh Sadeghlar} and {Christian Möhring} and {Christoph Boesecke} and {Kahtrin van Bremen} and {Gereon J. Rieke} and {Stefan Schlabe} and {Stefan Breitschwerdt} and {Milka Marinova} and {Ingo G. H. Schmidt-Wolf} and {Christian P. Strassburg} and {Anna-Maria Eis-Hübinger} and {Maria A. Gonzalez-Carmona}},
title = {Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer : does tumor entity matter?},
publisher = {AME Publishing Company},
year = 2023,
month = jun,
journal = {Journal of gastrointestinal oncology},
volume = 2023, vol. 14,
number = iss. 3,
pages = 1218--1234,
note = {Background: SARS-CoV-2 immunogenicity in patients with gastrointestinal cancer (GI cancer) following second and third vaccination was analyzed.
Methods: A total of 125 patients under active anticancer therapy or in follow-up care were included in this prospective study. Seroprevalence of SARS-CoV-2 anti-spike and surrogate neutralization antibodies (NABs) was measured.
Results: Four weeks after second vaccination, adequate titers of SARS-CoV-2 anti-spike immunoglobulin G (IgG) [≥282.0 binding antibody units (BAU)/mL] were found in 62.2% of patients under treatment versus 96.3% of patients in follow-up care (P<0.01). Sufficient titers of SARS-CoV-2 surrogate NAB (≥85.0%) were found in 32.7% of patients under treatment versus 70.6% in follow-up care (P<0.01). Titers of SARS-CoV-2 anti-spike IgG were especially low in patients with colorectal cancer (CRC). For SARS-CoV-2 surrogate NAB, patients with hepatocellular carcinoma (HCC) and with pancreaticobiliary cancer showed the lowest titers (P<0.01). SARSCoV-2 anti-spike IgG and SARS-CoV-2 surrogate NAB were associated with a correlation coefficient of 0.93. Reaching a titer of SARS-CoV-2 anti-spike IgG ≥482.0 BAU/mL, protective levels of SARS-CoV-2 surrogate NAB (≥85.0%) could be assumed. Following booster vaccination, all patients reached effective antibody titers.
Conclusions: Patients with active GI cancer showed impaired immunogenicity after second SARS-CoV-2 vaccination which was overcome by booster vaccination. Our findings were tumor-related and pronounced in patients with CRC and HCC. Waning immunity over time and antibody escape phenomena by variant of concern Omicron must be considered in these especially vulnerable patients.},
url = {https://hdl.handle.net/20.500.11811/13555}
}
author = {{Malte Benedikt Monin} and {Jens Gabriel Gorny} and {Moritz Berger} and {Leona I. Baier} and {Taotao Zhou} and {Robert Mahn} and {Farsaneh Sadeghlar} and {Christian Möhring} and {Christoph Boesecke} and {Kahtrin van Bremen} and {Gereon J. Rieke} and {Stefan Schlabe} and {Stefan Breitschwerdt} and {Milka Marinova} and {Ingo G. H. Schmidt-Wolf} and {Christian P. Strassburg} and {Anna-Maria Eis-Hübinger} and {Maria A. Gonzalez-Carmona}},
title = {Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer : does tumor entity matter?},
publisher = {AME Publishing Company},
year = 2023,
month = jun,
journal = {Journal of gastrointestinal oncology},
volume = 2023, vol. 14,
number = iss. 3,
pages = 1218--1234,
note = {Background: SARS-CoV-2 immunogenicity in patients with gastrointestinal cancer (GI cancer) following second and third vaccination was analyzed.
Methods: A total of 125 patients under active anticancer therapy or in follow-up care were included in this prospective study. Seroprevalence of SARS-CoV-2 anti-spike and surrogate neutralization antibodies (NABs) was measured.
Results: Four weeks after second vaccination, adequate titers of SARS-CoV-2 anti-spike immunoglobulin G (IgG) [≥282.0 binding antibody units (BAU)/mL] were found in 62.2% of patients under treatment versus 96.3% of patients in follow-up care (P<0.01). Sufficient titers of SARS-CoV-2 surrogate NAB (≥85.0%) were found in 32.7% of patients under treatment versus 70.6% in follow-up care (P<0.01). Titers of SARS-CoV-2 anti-spike IgG were especially low in patients with colorectal cancer (CRC). For SARS-CoV-2 surrogate NAB, patients with hepatocellular carcinoma (HCC) and with pancreaticobiliary cancer showed the lowest titers (P<0.01). SARSCoV-2 anti-spike IgG and SARS-CoV-2 surrogate NAB were associated with a correlation coefficient of 0.93. Reaching a titer of SARS-CoV-2 anti-spike IgG ≥482.0 BAU/mL, protective levels of SARS-CoV-2 surrogate NAB (≥85.0%) could be assumed. Following booster vaccination, all patients reached effective antibody titers.
Conclusions: Patients with active GI cancer showed impaired immunogenicity after second SARS-CoV-2 vaccination which was overcome by booster vaccination. Our findings were tumor-related and pronounced in patients with CRC and HCC. Waning immunity over time and antibody escape phenomena by variant of concern Omicron must be considered in these especially vulnerable patients.},
url = {https://hdl.handle.net/20.500.11811/13555}
}
The following license files are associated with this item:
